The three ETFs pursue an active investment strategy focussing on companies worldwide in the areas of disruptive innovation, artificial intelligence and genomics. When selecting companies, the investment manager uses both a top-down approach (thematic research to identify relevant securities) and a bottom-up approach (valuation, fundamental data and quantitative key figures of the individual companies, considering ESG criteria).

The ARK Innovation UCITS ETF invests in companies which are involved in disruptive innovations. These can be advances in scientific research and technological improvements in areas such as genomics, automation, manufacturing, transport, energy and artificial intelligence.

The ARK Artificial Intelligence & Robotics UCITS ETF focuses on companies in the fields of artificial intelligence, autonomous technologies and robotics.

The ARK Genomic Revolution UCITS ETF gives investors access to a portfolio of companies involved in the genomic revolution, focussing on extending and improving the quality of life of humans and other living beings. These companies can come from different sectors such as healthcare, IT or basic materials and develop, produce or manufacture bionic systems, bio-inspired computing, bioinformatics, molecular medicine and agricultural biotechnology.

The product offering in Deutsche Börse's XTF segment currently comprises a total of 2,154 ETFs. With this selection and an average monthly trading volume of around €14 billion, Xetra is the leading trading venue for ETFs in Europe.